Investigation of Blood Glucose and Insulin Response After Intake of Vitalose
1 other identifier
interventional
13
1 country
1
Brief Summary
The aim of this study is to assess the postprandial glucose and insulin response of Vitalose.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Oct 2020
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 28, 2020
CompletedFirst Posted
Study publicly available on registry
October 22, 2020
CompletedStudy Start
First participant enrolled
October 22, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2020
CompletedDecember 7, 2020
December 1, 2020
1 month
September 28, 2020
December 3, 2020
Conditions
Outcome Measures
Primary Outcomes (2)
2h iAUC for pp glucose response
Baseline, 15, 30, 45, 60, 90, 120 minutes
2h iAUC for pp insulin response
Baseline, 15, 30, 45, 60, 90, 120 minutes
Study Arms (4)
Vitalose
ACTIVE COMPARATORdissolved in water
isomaltulose
ACTIVE COMPARATORdissolved in water
sucrose
PLACEBO COMPARATORdissolved in water
glucose
PLACEBO COMPARATORdissolved in water
Interventions
Eligibility Criteria
You may qualify if:
- healthy adults
- Age 18-50 years
- BMI ≥18.5 and ≤30.0 kg/m²
You may not qualify if:
- acute or chronic disease
- food allergy or intolerance
- intake of medications which affect glucose tolerance
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Beneo-Institutelead
- BioTeSys GmbHcollaborator
Study Sites (1)
BioTeSys GmbH
Esslingen am Neckar, Germany
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Daniel Menzel, Dr.
BioTeSys GmbH
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- OTHER
- Intervention Model
- CROSSOVER
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 28, 2020
First Posted
October 22, 2020
Study Start
October 22, 2020
Primary Completion
December 1, 2020
Study Completion
December 1, 2020
Last Updated
December 7, 2020
Record last verified: 2020-12
Data Sharing
- IPD Sharing
- Will not share